The effect of 20 micrograms. desaminocysteine-D-arginine vasopressin intranasally on childhood nocturnal enuresis was studied in a randomized double-blind cross-over series of 54 children. The wetting was significantly less frequent during the 2, 3-week periods on desaminocysteine-D-arginine vasopressin than during placebo periods, or during periods without any treatment. The effect of desaminocysteine-D-arginine vasopressin was reproducible and the efficacy of desaminocysteine-D-arginine vasopressin depended on the frequency of wetting before treatment. After discontinuation of the short treatment enuresis recurred immediately. No side effects were noted. We conclude that desaminocysteine-D-arginine vasopressin may well be used in the management of childhood enuresis, especially in situations when an immediate effect is desirable.
No takes yet. Share an insight, caveat, or question.
Terho et al. (1984) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: